Status: Recruiting
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis
The study will evaluate safety and tolerance of intravenous delivery of GC304 gene therapy drug as a treatment of primary hypertriglyceridemic patients with previous onset of acute pancreatitis.
Participants needed: 7
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: GeneCradle IncUpdated: Jul 3, 2025Locations: 1
Eligibility criteria
Diagnosed as primary hypertriglyceridemia poorly managed by regular treatment an... [+5]
Patient who is known to be allergic to any ingredient of a trial drug (including... [+23]